News & Updates
Filter by Specialty:
Survivors cope with life after testicular cancer
Testicular cancer survivors (TCSs) demonstrate similar health-related quality of life (HRQoL) to that of the general population at a median of 28 years since treatment initiation, reports a study.
Survivors cope with life after testicular cancer
13 Jan 2024
Abiraterone plus prednisolone, enzalutamide a toss-up in castration-resistant prostate cancer
The combination of abiraterone plus prednisolone appears to have similar efficacy and safety as enzalutamide in the treatment of patients with nonmetastatic castration-resistant prostate cancer, according to a study.
Abiraterone plus prednisolone, enzalutamide a toss-up in castration-resistant prostate cancer
21 Dec 2023
MAGNITUDE updates in Asian cohort boost NIRA-AAP benefit in BRCA+ mCRPC
In the second interim analysis of the Asian cohort from the phase III MAGNITUDE study, a combination regimen comprising niraparib and abiraterone acetate plus prednisone (NIRA-AAP) improved clinical outcomes in patients with BRCA+ metastatic castration-resistant prostate cancer (mCRPC).
MAGNITUDE updates in Asian cohort boost NIRA-AAP benefit in BRCA+ mCRPC
13 Dec 2023
Biweekly cabazitaxel plus G-CSF beneficial to certain older mCRPC patients
In the treatment of older patients with metastatic castration-resistant prostate cancer (mCRPC) who are considered unsuitable candidates for standard cabazitaxel (CBZ) regimens, treatment with CBZ at 16 mg/m2 (biweekly CBZ16) plus prophylactic granulocyte colony–stimulating factor (G-CSF) at each cycle helps reduce the risk of higher grade neutropenia and/or neutropenic complications while yielding similar clinical outcomes, according to the results of the phase III CABASTY trial.
